TBPH
NASDAQ HealthcareTheravance Biopharma, Inc. - Ordinary Shares
Biotechnology
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
๐ Market Data
| Price | $16.79 |
|---|---|
| Volume | 293,240 |
| Market Cap | 864.94M |
| Beta | 0.170 |
| RSI (14-Day) | 56.0 |
| 200-Day MA | $15.95 |
| 50-Day MA | $15.95 |
| 52-Week High | $21.03 |
| 52-Week Low | $8.33 |
| P/E Ratio | 8.15 |
| Forward P/E | 12.39 |
| Price / Book | 2.89 |
๐ฏ Investment Strategy Scores
TBPH scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (51/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (15/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TBPH in your text
Paste any article, transcript, or post โ the tool will extract TBPH and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.